Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy in Locally Advanced Cutaneous Melanoma
2016-000317-78Phase 3Terminated
- Sponsor
- Provectus Biopharmaceuticals
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rose bengal in cutaneous melanoma (CM) and melanoma (2 arms), sponsored by Provectus Biopharmaceuticals. Primary endpoint: Progression-free survival (PFS). Started Jan 2021; status: terminated.
02
Drugs
rose bengal
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2016-000317-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000317-78.